Vladonix
A Khavinson-class thymus peptide bioregulator proposed to restore aging immune function by reactivating gene expression in thymic cells and T-lymphocytes.
Vladonix is a Khavinson-class peptide bioregulator derived from thymus tissue, developed within Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology. It is proposed to restore immune function in aging subjects by modulating gene expression in thymic epithelial cells and thymus-dependent lymphocyte populations, promoting T-cell maturation, normalizing CD4/CD8 ratios, and supporting cytokine balance. It shares its mechanistic framework and class-level evidence with thymalin, the better-characterized Khavinson thymus compound, but has no independent published clinical trials specific to this formulation.
Class
Short peptide complex (Khavinson-class thymus bioregulator)
Routes
Oral, Subcutaneous
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Immune restoration
Proposed to reactivate immune competence that declines with immunosenescence by modulating gene expression programs in thymic cells. Evidence is class-level, extrapolated from thymalin research rather than trials on this specific formulation.
T-cell support
Promotes T-cell maturation and, in the related thymalin extract, has stimulated differentiation of hematopoietic stem cells toward CD28+ T lymphocytes in vitro, supporting a role in rebuilding T-cell populations in aging subjects.
Thymic function
As a thymic tissue-derived bioregulator it is proposed to interact with chromatin regulatory elements in thymic epithelial cells to restore age-declined gene expression, potentially improving peripheral immune output.
CD4/CD8 balance
Reported to normalize CD4/CD8 ratios and support cytokine balance, mechanisms associated with restoring a more youthful immune signaling profile.
Longevity and anti-aging
Studied within the Khavinson geroprotective peptide program for its potential to counter lymphoid organ aging; effects are documented at the class level in review literature.
Mechanism
How it works
Vladonix is a short peptide complex proposed to penetrate cell nuclei and modulate gene expression in thymic and T-lymphocyte cells. By interacting with chromatin regulatory elements in thymic epithelial cells, it is thought to reactivate gene expression programs that decline with immunosenescence, thereby restoring T-cell maturation and peripheral immune competence.
Functionally, it is reported to promote T-cell maturation, normalize CD4/CD8 ratios, and support cytokine balance. These effects are consistent with the broader Khavinson bioregulator hypothesis, in which short organ-specific peptides act as epigenetic-level regulators that reactivate tissue-specific gene expression in the organ from which they are derived.
As a thymic tissue-derived bioregulator, Vladonix shares its mechanistic framework with thymalin, the better-characterized Khavinson thymus compound. Published research on thymus-derived short peptides, including thymalin, has demonstrated human hematopoietic stem cell differentiation activity and immune modulation in aged subjects, providing biological plausibility for this compound class. However, there are no independent published clinical trials specific to the Vladonix formulation.
Evidence
Research & clinical studies (2)
Thymalin Stimulates T-Lymphocyte Differentiation from Hematopoietic Stem Cells
Thymalin (the complex extract related to vladonix) stimulated differentiation of hematopoietic stem cells from CD117+ progenitors to CD28+ T lymphocytes in vitro, supporting immune-restorative activity relevant to age-related immune decline.
PMID 33237528Peptides and ageing
This Khavinson review describes the isolation and characterization of regulatory peptides including vladonix, documenting immunomodulatory and geroprotective effects on lymphoid organ aging and the regulatory role of tissue peptides in immune system longevity.
PMID 12374906Safety
Side effects & considerations
Contraindications & cautions
- Active or history of cancer
- Pregnancy or nursing
Generally considered lower risk in research contexts, but the safety profile of this specific formulation has not been established in controlled trials. Individual response varies; review all contraindications and consult a qualified healthcare professional before use.
FAQ
Vladonix — common questions
What is Vladonix?
Vladonix is a Khavinson-class peptide bioregulator derived from thymus tissue, developed as part of Vladimir Khavinson's organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology. It is proposed to restore immune function in aging subjects by modulating gene expression in thymic epithelial cells and thymus-dependent lymphocytes.
What is Vladonix primarily studied for?
It is studied for immune restoration, T-cell support, thymic function, longevity, and anti-aging.
How does Vladonix work?
It is a short peptide complex proposed to penetrate cell nuclei and modulate gene expression in thymic and T-lymphocyte cells, promoting T-cell maturation, normalizing CD4/CD8 ratios, and supporting cytokine balance.
What does the research show about Vladonix?
Direct evidence is limited to two sources. Related thymalin research stimulated differentiation of hematopoietic stem cells from CD117+ progenitors to CD28+ T lymphocytes in vitro, and a Khavinson review documents immunomodulatory and geroprotective effects of this peptide class. There are no independent published clinical trials specific to the Vladonix formulation.
How is Vladonix administered?
Reported routes are oral and subcutaneous. Standardized dosing protocols for this specific formulation are not available in the reviewed literature.
What are the contraindications for Vladonix?
Reported contraindications include active or a history of cancer and pregnancy or nursing. This is educational information only; consult a qualified healthcare professional before use.
Is Vladonix approved or legal?
Vladonix has no FDA approval and no approved indication in any Western jurisdiction. It is sold as a research-only compound, with use confined to the Russian integrative and anti-aging medicine context.
How is Vladonix related to thymalin?
Both are thymic tissue-derived Khavinson bioregulators that share the same mechanistic framework and class-level evidence. Vladonix is the commercial thymic bioregulator product distinct from thymalin but relying on the same class evidence, as it has no independent clinical trials of its own.
